Biliary Tract Neoplasms Clinical Trial
— CARPEGIEMOfficial title:
Multicenter Study of EUS-guided Gallbladder Drainage vs Choledochoduodenostomy as First Line in Malignant Distal Obstruction in Palliative Patients (CARPEGIEM Trial): an Open-label, Randomized Controlled Clinical Trial
NCT number | NCT06375967 |
Other study ID # | CARPEGIEM |
Secondary ID | |
Status | Not yet recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2024 |
Est. completion date | June 2027 |
The aim of the study is to evaluate technical, clinical and safety outcomes of lumen-apposing metal stent (LAMS) with a coaxial double-pigtail plastic stent (DPS) in EUS-guided choledochoduodenostomies vs cholcystogastrostomy for the management of malignant biliary obstruction in palliative patients.
Status | Not yet recruiting |
Enrollment | 128 |
Est. completion date | June 2027 |
Est. primary completion date | June 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Malignant distal biliary obstruction diagnosed in patient considered PALIATIVE with biliary drainage indication. - Consensual malignancy by a bilio-pancreatic multidisciplinar committe (histological confirmation is not mandatory) - Patient capable of understanding and/or singning the informed consent. - Patient who understands the type of study and will comply with all follow-up tests throughout its duration Exclusion Criteria: - Pregnancy or lactation. - Severe coagulation disorder: INR > 1.5 non correctable with plasma administration and/or platelet count < 50.000/mm3. - Previous cholecistectomy or gallblader perforation. - Tumoral obstruction of cystic duct. - Multiple liver metastases affecting more than 30% of the liver parenchyma - Distal malignant biliary strictures in patients considered resectable or borderline. - Benign or uncertain etiology of biliary strictures or strictures located proximally or in close proximity to the hilum. - Patients with prior biliary stents or other biliary drainages (e.g., PTCD). - Altered intestinal anatomy due to prior surgery that prevents or hinders papillary access ______________ (e.g., gastric bypass, Billroth II, duodenal switch, Roux-en-Y). - Gastric outlet obstruction. - Situations that do not allow for upper gastrointestinal endoscopy (e.g., esophageal stricture). - Patients with functional diversity, who lack the capacity to understand the nature and potential consequences of the study, except when a legal representative is available. - Patients incapable of maintaining follow-up appointments (lack of adherence). - Lack of informed consent. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitari de Bellvitge | L'Hospitalet De Llobregat | Barcelona, Catalonia |
Lead Sponsor | Collaborator |
---|---|
Hospital Universitari de Bellvitge | Complejo Hospitalario de Navarra, Complejo Hospitalario Universitario de Santiago, Complejo Hospitalario Universitario de Vigo, Hospital Clínico Universitario de Valencia, Hospital de Sant Pau, Hospital General Universitario de Alicante, Hospital General Universitario de Castellón, Hospital Mutua de Terrassa, Hospital Universitario Ramon y Cajal, University Hospital Virgen de las Nieves, University of Salamanca |
Spain,
Binda C, Anderloni A, Fugazza A, Amato A, de Nucci G, Redaelli A, Di Mitri R, Cugia L, Pollino V, Macchiarelli R, Mangiavillano B, Forti E, Brancaccio ML, Badas R, Maida M, Sinagra E, Repici A, Fabbri C, Tarantino I. EUS-guided gallbladder drainage using a lumen-apposing metal stent as rescue treatment for malignant distal biliary obstruction: a large multicenter experience. Gastrointest Endosc. 2023 Nov;98(5):765-773. doi: 10.1016/j.gie.2023.06.054. Epub 2023 Jun 29. — View Citation
Chen YI, Callichurn K, Chatterjee A, Desilets E, Fergal D, Forbes N, Gan I, Kenshil S, Khashab MA, Kunda R, Lam E, May G, Mohamed R, Mosko J, Paquin SC, Sahai A, Sandha G, Teshima C, Barkun A, Barkun J, Bessissow A, Candido K, Martel M, Miller C, Waschke K, Zogopoulos G, Wong C; ELEMENT trial and for the Canadian Endoscopic Research Collaborative (CERC). ELEMENT TRIAL: study protocol for a randomized controlled trial on endoscopic ultrasound-guided biliary drainage of first intent with a lumen-apposing metal stent vs. endoscopic retrograde cholangio-pancreatography in the management of malignant distal biliary obstruction. Trials. 2019 Dec 9;20(1):696. doi: 10.1186/s13063-019-3918-y. — View Citation
Garcia-Sumalla A, Loras C, Sanchiz V, Sanz RP, Vazquez-Sequeiros E, Aparicio JR, de la Serna-Higuera C, Luna-Rodriguez D, Andujar X, Capilla M, Barbera T, Foruny-Olcina JR, Martinez B, Dura M, Salord S, Laquente B, Tebe C, Videla S, Perez-Miranda M, Gornals JB; Spanish Working Group on Endoscopic Ultrasound Guided Biliary Drainage. Multicenter study of lumen-apposing metal stents with or without pigtail in endoscopic ultrasound-guided biliary drainage for malignant obstruction-BAMPI TRIAL: an open-label, randomized controlled trial protocol. Trials. 2022 Feb 25;23(1):181. doi: 10.1186/s13063-022-06106-1. Erratum In: Trials. 2022 Mar 14;23(1):214. — View Citation
Kamal F, Khan MA, Lee-Smith W, Sharma S, Acharya A, Farooq U, Aziz M, Kouanda A, Dai SC, Munroe CA, Arain M, Adler DG. Efficacy and safety of EUS-guided gallbladder drainage for rescue treatment of malignant biliary obstruction: A systematic review and meta-analysis. Endosc Ultrasound. 2023 Jan-Feb;12(1):8-15. doi: 10.4103/EUS-D-21-00206. — View Citation
Mangiavillano B, Moon JH, Facciorusso A, Vargas-Madrigal J, Di Matteo F, Rizzatti G, De Luca L, Forti E, Mutignani M, Al-Lehibi A, Paduano D, Bulajic M, Decembrino F, Auriemma F, Franchellucci G, De Marco A, Gentile C, Shin IS, Rea R, Massidda M, Calabrese F, Mirante VG, Ofosu A, Crino SF, Hassan C, Repici A, Larghi A. Endoscopic ultrasound-guided gallbladder drainage as a first approach for jaundice palliation in unresectable malignant distal biliary obstruction: Prospective study. Dig Endosc. 2024 Mar;36(3):351-358. doi: 10.1111/den.14606. Epub 2023 Jul 3. — View Citation
Teoh AYB, Napoleon B, Kunda R, Arcidiacono PG, Kongkam P, Larghi A, Van der Merwe S, Jacques J, Legros R, Thawee RE, Saxena P, Aerts M, Archibugi L, Chan SM, Fumex F, Kaffes AJ, Ma MTW, Messaoudi N, Rizzatti G, Ng KKC, Ng EKW, Chiu PWY. EUS-Guided Choledo — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SAFETY (ADVERSE EVENTS) | Safety will be measured by careful and comparative evaluation of adverse effects in both groups. | 12 months | |
Primary | Recurrent biliary obstruction | Recurrent biliary obstruction (RBO) has been defined as a composite endpoint of either occlusion or migration. | 12 months | |
Secondary | CLINICAL SUCCESS | Resolution of jaundice or drop in total bilirubin level by > 50% within 2 weeks after the EUS guided drainage. | 2 weeks | |
Secondary | TECHNICAL SUCCESS | Technical success was defined as successful placement of the LAMS between the bile duct (choledoc or gallblader) and the lumen digestive system (stomach or duodenum), creating a transmural ostomy. To evaluate the correct position of the transmural stent, the deployment of the internal flap in the lumen of the bile duct must be verified by ultrasound vision and the internal flap by endoscopic vision. | 24 hours | |
Secondary | BILIARY REINTERVENTIONS (BRI) | Interventions needed to treat - Recurrent biliary obstruction (RBO) has been defined as a composite endpoint of either occlusion or migration. | 12 months | |
Secondary | HOSPITAL STAY | Length of hospital stay after intervention | 12 months | |
Secondary | MORTALITY | Overall mortality throughout the study | 12 months | |
Secondary | COST ANALYSIS | Evaluate the costs between the two types of strategy | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
Completed |
NCT03101566 -
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
|
Phase 2 | |
Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
Not yet recruiting |
NCT06037655 -
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
|
Phase 2 | |
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A | |
Completed |
NCT02558959 -
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
|
Phase 2 | |
Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
Completed |
NCT02784353 -
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
|
N/A | |
Recruiting |
NCT05429203 -
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
|
N/A | |
Recruiting |
NCT02255669 -
Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction
|
N/A | |
Completed |
NCT01731821 -
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
|
Phase 3 | |
Completed |
NCT00422409 -
Endoscopic Stenting of Gastrointestinal Cancer
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
Terminated |
NCT02615210 -
Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures
|
N/A | |
Completed |
NCT04595058 -
LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent
|
N/A | |
Recruiting |
NCT04856761 -
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
|
||
Recruiting |
NCT03427242 -
Apatinib for Advanced Biliary Carcinoma
|
Phase 2 | |
Recruiting |
NCT05615818 -
Personalized Medicine for Advanced Biliary Cancer Patients
|
Phase 3 |